EUVIMEDEUVIMED entdecken
Open Access

Toxicity Adaptive Lists Design: A Practical Design for Phase I Drug Combination Trials in Oncology

Massimiliano Russo iD, Francesco Mariani iD, James M Cleary iD, Geoffrey I Shapiro iD, Gregory M Coté iD, Lorenzo Trippa iD

JCO Precision Oncology · 2024

DOI: 10.1200/po.24.00275 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Massimiliano Russo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Statistics, The Ohio State University, Columbus, OH. Hauptthemen laut MEDLINE: Clinical Trials, Phase I as Topic, Research Design, Maximum Tolerated Dose. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NLM NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE We introduce a novel algorithmic approach to design phase I trials for oncology drug combinations. METHODS Our proposed Toxicity Adaptive Lists Design (TALE) is straightforward to implement, requiring the prespecification of a small number of parameters that define rules governing dose escalation, de-escalation, or reassessment of previously explored dose levels. These rules effectively regulate dose exploration and control the number of toxicities. A key feature of TALE is the possibility of simultaneous assignment of multiple-dose combinations that are deemed safe by previously accrued data. RESULTS A numerical study shows that TALE shares comparable operative characteristics, in terms of identification of the maximum tolerated dose (MTD), to alternative approaches such as the Bayesian optimal interval design, the COPULA, the product of independent beta probabilities escalation, and the continual reassessment method for partial ordering designs while reducing the risk of overdosing patients. CONCLUSION The proposed TALE design provides a favorable balance between maintaining patient safety and accurately identifying the MTD. To facilitate the use of TALE, we provide a user-friendly R Shiny application and an R package for computing relevant operating characteristics, such as the risk of assigning highly toxic dose combinations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase I as TopicResearch DesignMaximum Tolerated DoseHumansNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAlgorithmsAntineoplastic AgentsBayes Theorem

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Statistics, The Ohio State University, Columbus, OH.
  • Dipartimento di Scienze Statistiche, Sapienza University of Rome, Rome, Italy.
  • Dana-Farber Cancer Institute, Boston, MA.
  • Harvard Medical School, Boston, MA.
  • Mass General Cancer Center, Boston, MA.
  • T.H. Chan School of Public Health, Harvard University, Cambridge, MA.

ORCID-Profile: Massimiliano Russo, Francesco Mariani, James M Cleary, Geoffrey I Shapiro, Gregory M Coté, Lorenzo Trippa

Förderung

  • NLM NIH HHS
  • NCI NIH HHS

Zitieren

APA

Russo, M., Mariani, F., Cleary, J. M., Shapiro, G. I., Coté, G. M., & Trippa, L. (2024). Toxicity Adaptive Lists Design: A Practical Design for Phase I Drug Combination Trials in Oncology. JCO Precision Oncology. https://doi.org/10.1200/po.24.00275

Vancouver

Russo M, Mariani F, Cleary JM, Shapiro GI, Coté GM, Trippa L. Toxicity Adaptive Lists Design: A Practical Design for Phase I Drug Combination Trials in Oncology. JCO Precision Oncology. 2024. doi:10.1200/po.24.00275

BibTeX
@article{Russo2024,
  author = {Russo, Massimiliano and Mariani, Francesco and Cleary, James M and Shapiro, Geoffrey I and Coté, Gregory M and Trippa, Lorenzo},
  title = {Toxicity Adaptive Lists Design: A Practical Design for Phase I Drug Combination Trials in Oncology},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.24.00275}
}
Kostenlos starten →